2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Muhammad Bilal Abid, MD, MRCP, discusses challenges with CAR-T cell therapy during the coronavirus disease 2019 pandemic.
Muhammad Bilal Abid, MD, MRCP, assistant professor of medicine in the Divisions of Hematology/Oncology and Infectious Diseases at the Medical College of Wisconsin, discusses challenges with CAR-T cell therapy during the coronavirus disease 2019 (COVID-19) pandemic.
COVID-19 has caused many disruptions in the administration of CAR T-cell therapy, says Abid. As such, several considerations need to be taken into account.
To mitigate the risk of severe cytokine release syndrome, CAR T-cell therapy should be brought to a temporary halt, Abid explains. Doing so will prevent dysfunctional T cells and an elevation of inflammatory cytokines.
After stopping CAR T-cell therapy, it is critical to closely monitor patients, Abid concludes.